According to Zhitong Financial App, Quanxin Bio-B (02509.HK) announced that on December 19, 2025, the company signed a licensing and cooperation agreement with LE2025 Therapeutics AG (LE2025), a subsidiary of Windward Bio Group AG (Windward Bio). The agreement grants LE2025 the exclusive right to develop and commercialize the QX027N on a global scale (excluding mainland China, Taiwan, Hong Kong Special Administrative Region of China and Macau Special Administrative Region of China) (license area). In return, the Company or its designated subsidiaries (collectively, the “Group”) will be entitled to receive payments totaling up to $700 million, including down payments, Windward Bio's equity, development and commercial milestone payments, and tiered royalties based on QX027N's net sales in the licensed region. Qx027n is a long-acting anti-TSLPxIL-13 bispecific antibody independently developed by the company.

According to Zhitong Financial App, Quanxin Bio-B (02509.HK) announced that on December 19, 2025, the company signed a licensing and cooperation agreement with LE2025 Therapeutics AG (LE2025), a subsidiary of Windward Bio Group AG (Windward Bio). The agreement grants LE2025 the exclusive right to develop and commercialize the QX027N on a global scale (excluding mainland China, Taiwan, Hong Kong Special Administrative Region of China and Macau Special Administrative Region of China) (license area). In return, the Company or its designated subsidiaries (collectively, the “Group”) will be entitled to receive payments totaling up to $700 million, including down payments, Windward Bio's equity, development and commercial milestone payments, and tiered royalties based on QX027N's net sales in the licensed region. Qx027n is a long-acting anti-TSLPxIL-13 bispecific antibody independently developed by the company.